Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry.
In vitro biosynthesis using pooled human liver microsomes was applied to help identify in vivo metabolites of ketamine by liquid chromatography (LC)-tandem mass spectrometry. Microsomal synthesis produced dehydronorketamine, seven structural isomers of hydroxynorketamine, and at least five structural isomers of hydroxyketamine. To aid identification, stable isotopes of the metabolites were also produced from tetra-deuterated isotopes of ketamine or norketamine as substrates. Five metabolites (three hydroxynorketamine and two hydroxyketamine isomers) gave chromatographically resolved components with product ion spectra indicating the presence of a phenolic group, with phenolic metabolites being further substantiated by selective liquid-liquid extraction after adjustments to the pH. Two glucuronide conjugates of hydroxynorketamine were also identified. Analysis by LC-coupled ion cyclotron resonance mass spectrometry gave unique masses in accordance with the predicted elemental composition. The metabolites, including the phenols, were subsequently confirmed to be present in urine of subjects after oral ketamine administration, as facilitated by the addition of deuterated metabolites generated from the in vitro biosynthesis. To our knowledge, phenolic metabolites of ketamine, including an intact glucuronide conjugate, are here reported for the first time. The use of biologically synthesized deuterated material as an internal chromatographic and mass spectrometric marker is a viable approach to aid in the identification of metabolites. Metabolites that have particular diagnostic value can be selected as candidates for chemical synthesis of standards.
Turfus
Sophie C
SC
Department of Forensic Science & Drug Monitoring, King's College London, 150 Stamford Street, London, UK.
Parkin
Mark C
MC
Cowan
David A
DA
Halket
John M
JM
Smith
Norman W
NW
Braithwaite
Robin A
RA
Elliot
Simon P
SP
Steventon
Glyn B
GB
Kicman
Andrew T
AT
D000284:Administration, Oral; D000778:Anesthetics, Dissociative / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics* / Q000652:urine; D001711:Biotransformation; D002853:Chromatography, Liquid; D003243:Consciousness / Q000187:drug effects; D017357:Cyclotrons; D003903:Deuterium; D005260:Female; D005583:Fourier Analysis; D020719:Glucuronides / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007536:Isomerism; D007649:Ketamine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine; D008297:Male; D055432:Metabolomics / Q000379:methods*; D008862:Microsomes, Liver / Q000201:enzymology*; D015394:Molecular Structure; D010636:Phenols / Q000378:metabolism; D015203:Reproducibility of Results; D021241:Spectrometry, Mass, Electrospray Ionization; D015813:Substance Abuse Detection; D053719:Tandem Mass Spectrometry
D000778:Anesthetics, Dissociative; D020719:Glucuronides; D010636:Phenols; D007649:Ketamine; C053741:6-hydroxyketamine; D003903:Deuterium; C033419:norketamine